Shares of WuXi XDC Cayman Inc, a Chinese contract research organization, surged 5.09% in intraday trading on Wednesday, following the company's bullish earnings guidance.
WuXi XDC announced that it expects its revenue for the fiscal year to exceed the corresponding amounts for the year ended December 31, 2023, by more than 85%. Additionally, the company forecasts its net profit to surge by 260% and its adjusted net profit to increase by over 170% compared to the previous year.
The robust earnings outlook, driven by strong demand for the company's services, fueled investor optimism and propelled the stock higher. Analysts suggest that WuXi XDC's strong performance reflects the growing importance of contract research organizations in the pharmaceutical industry.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。